Business · 25/10/20261 min read
The Results of Phase III OptiTROP-Lung06 Study of Sacituzumab Tirumotecan (sac-TMT) Presented as an ESMO Oral Presentation and Simultaneously Published in The New England Journal of Medicine
Summary
The source item contains limited metadata.
Original source language: PR Newswire — Global News ReleasesOpen original release →